(Q35925413)

English

Bortezomib induces apoptosis and growth suppression in human medulloblastoma cells, associated with inhibition of AKT and NF-ĸB signaling, and synergizes with an ERK inhibitor

scientific article published in April 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

11 August 2017

Bortezomib induces apoptosis and growth suppression in human medulloblastoma cells, associated with inhibition of AKT and NF-ĸB signaling, and synergizes with an ERK inhibitor (English)

1 reference

Europe PubMed Central

11 August 2017

medulloblastoma

0 references

2

object named as

Veronica Jove

0 references

author name string

Fan Yang

1

1 reference

Europe PubMed Central

11 August 2017

Veronica Jove

2

1 reference

Europe PubMed Central

11 August 2017

Shirley Chang

3

1 reference

Europe PubMed Central

11 August 2017

Michael Hedvat

4

1 reference

Europe PubMed Central

11 August 2017

Lucy Liu

5

1 reference

Europe PubMed Central

11 August 2017

Ralf Buettner

6

1 reference

Europe PubMed Central

11 August 2017

Yan Tian

7

1 reference

Europe PubMed Central

11 August 2017

Anna Scuto

8

1 reference

Europe PubMed Central

11 August 2017

Wei Wen

9

1 reference

Europe PubMed Central

11 August 2017

M L Richard Yip

10

1 reference

Europe PubMed Central

11 August 2017

Timothy Van Meter

11

1 reference

Europe PubMed Central

11 August 2017

Yun Yen

12

1 reference

Europe PubMed Central

11 August 2017

Richard Jove

13

1 reference

Europe PubMed Central

11 August 2017

publication date

1 April 2012

1 reference

Europe PubMed Central

11 August 2017

Cancer Biology and Therapy

1 reference

Europe PubMed Central

11 August 2017

13

1 reference

Europe PubMed Central

11 August 2017

6

1 reference

Europe PubMed Central

11 August 2017

349-357

1 reference

Europe PubMed Central

11 August 2017

Knockdown of survivin (BIRC5) causes apoptosis in neuroblastoma via mitotic catastrophe

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3341212

2 October 2017

Clinical significance of interleukin (IL)-6 in cancer metastasis to bone: potential of anti-IL-6 therapies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3341212

2 October 2017

STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3341212

2 October 2017

Sorafenib induces growth arrest and apoptosis of human glioblastoma cells through the dephosphorylation of signal transducers and activators of transcription 3

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3341212

2 October 2017

Interleukin-6 in the bone marrow microenvironment promotes the growth and survival of neuroblastoma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3341212

2 October 2017

Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3341212

2 October 2017

Ursolic acid inhibits STAT3 activation pathway leading to suppression of proliferation and chemosensitization of human multiple myeloma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3341212

2 October 2017

Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3341212

2 October 2017

Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3341212

2 October 2017

Cell survival, cell death and cell cycle pathways are interconnected: implications for cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3341212

2 October 2017

Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3341212

2 October 2017

Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3341212

2 October 2017

Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3341212

2 October 2017

Mechanisms of disease: Insights into the emerging role of signal transducers and activators of transcription in cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3341212

2 October 2017

Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3341212

2 October 2017

Roles and regulation of stat family transcription factors in human breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3341212

2 October 2017

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3341212

2 October 2017

The STATs of cancer--new molecular targets come of age

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3341212

2 October 2017

Neuroblastoma: biological insights into a clinical enigma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3341212

2 October 2017

Stat3 as an oncogene

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3341212

2 October 2017

Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3341212

2 October 2017

1 reference

https://api.crossref.org/works/10.4161%2FCBT.19239

21 January 2018

The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation

1 reference

https://api.crossref.org/works/10.4161%2FCBT.19239

21 January 2018

Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.4161%2FCBT.19239

21 January 2018

gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis.

1 reference

https://api.crossref.org/works/10.4161%2FCBT.19239

21 January 2018

1 reference

https://pubmed.ncbi.nlm.nih.gov/22313636

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

1 reference

https://pubmed.ncbi.nlm.nih.gov/22313636

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of sorafenib in patients with advanced hepatocellular carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/22313636

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Blockade of tumor growth due to matrix metalloproteinase-9 inhibition is mediated by sequential activation of beta1-integrin, ERK, and NF-kappaB.

1 reference

12 January 2024

https://opencitations.net/index/api/v1/citations/10.1074/JBC.M707931200

Identifiers

10.4161/CBT.19239

1 reference

Europe PubMed Central

11 August 2017

1 reference

Europe PubMed Central

11 August 2017

1 reference

Europe PubMed Central

11 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35925413&oldid=2052817762"